CLAIMS

1. Use of at least one alphavirus in the manufacture of an antitumour drug, for treating a tumour wherein, said alphavirus is selected from an M1 virus and a Getah virus and the tumour is a ZAP low expression tumour or a ZAP negative tumour.

2. The use of claim 1, wherein the tumour is a solid tumour.

3. The use of claim 1 or 2, wherein, the tumour is liver cancer, colorectal cancer, bladder cancer, breast cancer, cervical cancer, prostate cancer, glioma, melanoma, pancreatic cancer, nasopharyngeal carcinoma, lung cancer, or gastric cancer.

4. The use of any one of the preceding claims wherein, the antitumour drug is an injection, tablet, capsule or patch.

5. The use of any one of the preceding claims, wherein the genome of said at least one alphavirus has at least 97.8% nucleotide sequence identity to the genome of the M1 virus deposited under Accession No. CCTCC V201423.

6. The use of any one of the preceding claims, wherein the genome of said at least one alphavirus has 100% nucleotide sequence identity to the genome of the M1 virus deposited under Accession No. CCTCC V201423.

7. An antitumour administration system, comprising a ZAP expression level detecting reagent and at least one alphavirus, wherein the alphavirus is selected from an M1 virus and a Getah virus; and when using the system, the ZAP expression level detecting reagent is first applied to detect the ZAP expression level of the subject, and if the ZAP is low or negative expressed, said alphavirus is then administrated to the subject.

8. An antitumour drug, comprising at least one alphavirus and a ZAP inhibitor(s), wherein said alphavirus is selected from an M1 virus and a Getah virus.

9. The drug of claim **8**, wherein, the ZAP inhibitor is a tumour targeted ZAP inhibitor.

10. The drug of claim 8 or 9, wherein the genome of said at least one alphavirus has at least 97.8% nucleotide sequence identity to the genome of the M1 virus deposited under Accession No. CCTCC V201423.

11. The drug of claim 8 or 9, wherein the genome of said at least one alphavirus has 100% nucleotide sequence identity to the genome of the M1 virus deposited under Accession No. CCTCC V201423.

12. The use or antitumour administration system or drug according to any one of the preceding claims, wherein said at least one alphavirus is selectively enriched in tumour tissue after administration.